Stanford spent more than 20 years developing a blood-cancer transplant therapy; its first commercial patient has now been treated after a trial found 78% were free from moderate-to-severe GVHD at one year

• Representative Image (AI-generated)A blood-cancer treatment that Stanford researchers have spent more than two decades developing has now reached an important milestone.
• Its first commercial patient has been treated following U.